KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Non-Current Deffered Revenue (2018 - 2021)

Castle Biosciences' Non-Current Deffered Revenue history spans 4 years, with the latest figure at $172000.0 for Q1 2021.

  • On a quarterly basis, Non-Current Deffered Revenue rose 218.52% to $172000.0 in Q1 2021 year-over-year; TTM through Mar 2021 was $172000.0, a 218.52% increase, with the full-year FY2020 number at $1.7 million, changed N/A from a year prior.
  • Non-Current Deffered Revenue hit $172000.0 in Q1 2021 for Castle Biosciences, down from $1.7 million in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for CSTL hit a ceiling of $1.7 million in Q4 2020 and a floor of $44000.0 in Q4 2018.
  • Historically, Non-Current Deffered Revenue has averaged $524837.0 across 4 years, with a median of $114345.0 in 2019.
  • Biggest five-year swings in Non-Current Deffered Revenue: surged 1935.5% in 2020 and later soared 218.52% in 2021.
  • Tracing CSTL's Non-Current Deffered Revenue over 4 years: stood at $44000.0 in 2018, then rose by 27.29% to $56006.0 in 2019, then soared by 2997.88% to $1.7 million in 2020, then tumbled by 90.09% to $172000.0 in 2021.
  • Business Quant data shows Non-Current Deffered Revenue for CSTL at $172000.0 in Q1 2021, $1.7 million in Q4 2020, and $1.1 million in Q3 2020.